Xarelto Regulatory Post-Marketing Surveillance.
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Rivaroxaban (Primary) ; Aspirin; Fondaparinux sodium; Low molecular weight heparins; Vitamin K antagonists
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Adverse reactions
- Sponsors Bayer
- 26 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 15 Apr 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 16 Mar 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Mar 2015 as per ClinicalTrials.gov record.